| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | KMT6B |
| Entrez GeneID | 2145 |
| clone | 4B11B4 |
| WB Predicted band size | 85.3kDa |
| Host/Isotype | Mouse IgG2a |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human EZH1 (AA: 135-294) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是3-4条关于EZH1抗体的参考文献示例(注：内容为模拟虚构，实际文献需通过数据库检索确认)：
---
1. **文献名称**: "EZH1 and EZH2 as Components of the Polycomb Repressive Complex 2: Distinct Roles in Hematopoietic Differentiation"
**作者**: Margueron R, et al.
**摘要**: 本研究比较了EZH1和EZH2在造血系统中的功能差异，通过EZH1抗体检测发现，EZH1在维持干细胞静息状态中起关键作用，而EZH2更参与分化调控。实验表明EZH1的缺失导致造血干细胞异常增殖。
---
2. **文献名称**: "EZH1 Overexpression Correlates with Poor Prognosis in Acute Myeloid Leukemia"
**作者**: Herviou L, et al.
**摘要**: 通过免疫组化(使用EZH1特异性抗体)分析白血病患者样本，发现EZH1在AML细胞中高表达，且与化疗耐药性和总生存率降低显著相关，提示其作为潜在治疗靶点。
---
3. **文献名称**: "EZH1-Mediated H3K27 Trimethylation Promotes Tumor Invasion in Solid Cancers"
**作者**: Yamagishi M, et al.
**摘要**: 研究利用EZH1抗体在乳腺癌和肺癌模型中验证了EZH1通过表观遗传沉默抑癌基因驱动肿瘤转移的机制，抑制EZH1可减少体内外侵袭能力。
---
4. **文献名称**: "Development of a High-Specificity Monoclonal Antibody for EZH1 and Its Application in Epigenetic Drug Screening"
**作者**: Kim KH, et al.
**摘要**: 报道了一种新型EZH1单克隆抗体的开发，验证了其在ChIP-seq和Western blot中的高特异性，并用于筛选靶向EZH1的小分子抑制剂，为癌症治疗提供新工具。
---
如需具体文献，建议通过PubMed、Web of Science或Google Scholar检索关键词“EZH1 antibody” + 研究领域(如癌症、表观遗传学等)。
The EZH1 antibody is a key tool for studying the function of Enhancer of Zeste Homolog 1 (EZH1), a catalytic subunit of the Polycomb Repressive Complex 2 (PRC2). EZH1 shares homology with EZH2. both functioning as histone methyltransferases responsible for trimethylating lysine 27 on histone H3 (H3K27me3), a hallmark of transcriptionally repressive chromatin. However, EZH1 and EZH2 exhibit distinct biological roles. While EZH2 dominates PRC2 activity in proliferating cells, EZH1 is more prominent in post-mitotic or differentiated cells, acting as a modulator of gene silencing in tissues with low cell turnover, such as skeletal muscle, neurons, and hematopoietic stem cells. This functional divergence arises from differences in their enzymatic kinetics and PRC2 complex-binding preferences.
EZH1 antibodies are widely used to investigate its role in epigenetic regulation, developmental processes, and diseases, particularly cancer. Studies reveal that EZH1 can compensate for EZH2 loss in certain contexts, contributing to tumor progression or suppression depending on cellular conditions. Researchers employ these antibodies in techniques like chromatin immunoprecipitation (ChIP), Western blotting, and immunofluorescence to map EZH1’s genomic targets, quantify expression, or assess its subcellular localization. Validation of antibody specificity is critical due to structural similarities between EZH1 and EZH2. often requiring knockout controls or isoform-specific validation assays. Recent interest in EZH1 stems from its emerging therapeutic relevance, as dual EZH1/EZH2 inhibitors are being explored for cancer treatment.
×
